ClinicalTrials.gg
CompletedNCT02630329NOTABLEUpdated Jun 11, 2020

Notes Adnexectomy for Benign Pathology Compared to Laparoscopic Excision

An interventional study of vNOTES adnexectomy and Laparoscopic adnexectomy in Natural Orifice Endoscopic Surgery, Disease, Adnexal and Laparoscopic Surgery, sponsored by Imelda Hospital, Bonheiden. Completed at 1 site in Belgium. Open to female participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-06-11.

Sponsored by Imelda Hospital, Bonheiden · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Study summary

Objective: To compare vNOTES (vaginal Natural Orifice Transluminal Endoscopic Surgery) and established laparoscopic removal of benign adnexal masses Study design: Randomized controlled/single center/single-blinded/parallel-group/non-inferiority/efficacy trial.

Study population: Women aged 18 to 70 years with symptomatic or persistent benign adnexal masses detected by clinical examination and ultrasound.

Randomization: Women will be randomly allocated to undergo one of two techniques for removal of the benign adnexal mass immediately before surgery by using a computer generated randomization list. The investigators will use stratified randomization according to the cyst diameter.

Intervention: Women will be treated by a surgeon who is not blinded to the treatment allocation and who is equally skilled in performing both techniques. In the intervention group a vNOTES technique will be used.

Control: In the control group surgery will be done by a classical laparoscopic technique.

Participants, nursing staff and outcome assessors will be blinded.

Main study parameters/endpoints:

Primary outcomes: successful removal of a benign adnexal mass without spill. Secondary outcomes: the proportion of women discharged the same day based on their own preference; postoperative pain scores using a VAS (Visual Analogue Scale) measured between day 1 till 7 by the participating women following surgery and the total amount of analgesics used as described in the standardized pain treatment protocol between day 1 till 7; postoperative infection defined by lower abdominal pain with fever > 38°C and positive clinical signs or laboratory findings; per- or postoperative complications according to the Clavien- Dindo classification detected during the first six weeks of surgery; duration of the surgical procedure; incidence and intensity of dyspareunia recorded by the participants at 3 and 6 months by self-reporting using a simple questionnaire and VAS scale; sexual wellbeing recorded by the participants at 3 and 6 months by SSFS (Short Sexual Functioning Scale); direct costs associated up to 6 weeks after the surgical intervention with both procedures.

Read the detailed description
  1. Objectives of the NOTABLE Trial

The primary research questions of this IDEAL stage 2b efficacy trial are as follows: is a vNOTES adnexectomy at least as effective compared to the standard transabdominal laparoscopic approach (LSC) for removing a benign adnexal mass without spill? (non-inferiority design)

Secondary research questions are:

  • Do more women treated by vNOTES prefer to leave the hospital on the day of surgery compared to LSC?
  • Do women treated by vNOTES suffer from less pain compared to women treated by LSC in the first postoperative week?
  • Is the removal of a benign adnexal mass by vNOTES faster compared to LSC?
  • Does a vNOTES cause more pelvic infection or other complications compared to LSC?
  • Does a vNOTES cause more hospital readmissions within 6 weeks following surgery compared to LSC?
  • Does a vNOTES approach result in more women reporting dyspareunia, less sexual wellbeing or less health-related quality of life at 3 or 6 months after surgery when compared to women treated by LSC?
  • What are the direct and indirect costs up to 6 weeks of a vNOTES compared to LSC?

TRIAL DESIGN 2.1. Design A single center, single-blinded, parallel group randomized, non-inferiority efficacy trial.

2.2. Simple pilot randomized trial: minimal extra workload 2.3. Time schedule Based upon the mean number of laparoscopic adnexectomies performed annually at the department of Obstetrics and Gynecology of the participating center (36) the investigators estimate that the duration of recruitment will be 21 months. Based upon the follow up (6 months) and the period of analysis/reporting (3 months) the total study period will be 2.5 years.

2.4. Participating center Department of Obstetrics and Gynecology Imeldahospital Imeldalaan 9 2820 Bonheiden Belgium

  1. ELIGIBILITY, CONSENT AND RANDOMIZATION 3.1. Screening and consent prior to surgery All women aged 18 to 70 years regardless of parity presenting with a symptomatic or asymptomatic persistent benign adnexal mass on clinical examination confirmed by ultrasound are eligible for inclusion. The diagnosis of benign adnexal mass will be based upon the prospectively validated IOTA classification(International Ovarian Tumour Analysis Group) simple ultrasound rules to distinguish between benign and malignant adnexal masses.

3.2. Determining eligibility All women aged 18 to 70 years regardless of parity presenting with a symptomatic or asymptomatic persistent benign adnexal mass on clinical examination who provide consent to participation are eligible in the NOTABLE trial based on the findings of the ultrasound findings and will be randomized before the procedure.

3.3. Randomization If the woman is eligible for the NOTABLE trial, the trial secretary will obtain a randomized allocation the day before surgery. This will be done using a randomization list generated by a free computer software program offered by Research Randomizer (https://www.randomizer.org). The random sequence generation will be concealed using sequentially numbered opaque sealed envelopes. The envelope will be opened by the nurse assistant on the day before the surgical intervention for logistic reasons. The investigators will use stratified randomization in this small pilot RCT (randomized controlled trial) according to the cyst diameter.

3.4. Patients with strong preference for treatment A minority of women will express a clear preference for one of both treatments (e.g. strong desire to have no scar) and for this reason will not wish to be randomized between surgical treatments. To investigate how outcomes vary by choice, these women could be followed up in exactly the same way as for those women randomized into the NOTABLE trial. A formal non-randomized follow-up of these women will not be done for simple logistical reasons.

3.5. Stratification of randomization A blocked randomization procedure will be used to avoid chance imbalances for the parameter 'cyst diameter'.

To avoid any possibility of foreknowledge, the randomized allocation will not be given until all eligibility and stratification data have been given.

  1. TREATMENT ALLOCATIONS 4.1. Surgical procedures The principal investigator, who has training and experience in both laparoscopy and NOTES, will perform all surgical procedures. He is therefore not blinded. All vNOTES participants will be blinded by three superficial "mock" skin incisions similar to those routinely done with the laparoscopic technique.

4.1.1 vNOTES adnexectomy This is the surgical procedure done in the intervention arm of the NOTABLE trial.

4.1.2 LSC adnexectomy This is the surgical procedure done in the control arm of the NOTABLE trial. 5. FOLLOW-UP AND OUTCOME MEASURES 5.1. Clinical assessments 5.1.1 Format PROMs will be collected using a postal questionnaire, which will include a combination of disease specific and generic measurement instruments.

The postal questionnaires will be sent from the NOTABLE Trial Office with postage paid envelopes two weeks before the due date. Reminders will be sent to the participants if the questionnaire is not returned within one week of the due date and attempts will be made to contact the women by phone if the questionnaire is not returned by two weeks after the due date.

5.1.2 Timing of assessments The primary outcome will be measured clinically at the end of the surgical procedure. In addition patient reported outcome measures (PROMs) will take place the evening of the surgical intervention (return home), during the first postoperative week (pain by Visual Analogue (VAS)scores and analgetic drugs) and at 3 and 6 months (dyspareunia/ sexual well being/ health related quality of life). Clinical physician assessment will take place the evening of the surgical intervention (return home) and during the first six weeks following surgery (pelvic infection, surgical complications, hospital readmission rate).

5.2. Primary clinical outcome measure The proportion of women successfully treated by removing the adnexal mass without spill, using a dichotomous outcome measure, will be used as a measure of efficacy.

5.3. Secondary clinical outcome measures

The following secondary outcomes will be measured:

  • The proportion of women admitted in-hospital for at least one night observation based on their own preference, as a dichotomous outcome.
  • Postoperative pain scores, as an ordinal outcome, measured using a Visual Analogue Scale (VAS) scale twice daily from day 1 till 7 self-reported by the participating women. VAS scores range from 0=no pain to 10= worst imaginable pain.
  • Postoperative pain defined by the total amount of analgesics used as described in the standardized pain treatment protocol, as a continuous outcome.
  • Postoperative infection as a dichotomous outcome.
  • Per- or postoperative complications according to the Clavien- Dindo classification detected during the first six weeks of surgery, as a dichotomous outcome.
  • Hospital readmission within 6 weeks following surgery, as a dichotomous outcome.
  • Incidence and intensity of dyspareunia recorded by the participants at 3 and 6 months by self-reporting using a simple questionnaire and Visual Analogue Scale (VAS) scale, as a dichotomous and ordinal outcome. VAS scores range from 0=no pain to 10= worst imaginable pain.
  • Sexual wellbeing at baseline, at 3 and 6 months by self-reporting the Short Sexual Functioning Scale (SSFS). The SSFS is a questionnaire with 7 open ended questions on sexual wellbeing.
  • Health-related quality of life, at baseline, at 3 and 6 months by self-reporting the EQ-5D-3L tool consisting of a questionnaire on 5 domains and a scale ranging from 0=worst possible health-related quality of life to 100 = best possible health-related quality of life.
  • Duration of surgery measured as the time in minutes from the insertion of the bladder catheter to the end of vaginal/abdominal wound closure, as a continuous outcome.

5.4. Health economic outcomes The direct and indirect costs of both techniques up to 6 weeks after the surgical intervention will be calculated.

  1. ACCRUAL AND ANALYSIS 6.1. Sample size The sample size for this trial has been chosen to give good statistical power to preclude any clinically important inferiority of vNOTES compared to laparoscopy and is based on evidence retrieved from a systematic review of the literature and a RCT comparing the excision of mature teratoma using culdotomy with and without laparoscopy. Based on the power calculations for the primary outcome and two secondary outcomes and assuming a loss-to-follow-up rate of 10% the investigators decided to include 66 study participants in the NOTABLE trial.

6.2. Projected accrual and attrition rates It is anticipated that recruitment of participants will take two years. Based upon the mean number of laparoscopic adnexectomies performed annually at the department of Obstetrics and Gynecology of the participating center (36) the investigators estimate that the duration of recruitment will be 21 months. Based upon the follow up (6 months) and the period of analysis/reporting (3 months) the total study period will be 2.5 years. First publication will be possible within four years of trial commencement.

02

Conditions studied

  • Natural Orifice Endoscopic Surgery
  • Disease, Adnexal
  • Laparoscopic Surgery

Keywords

  • NOTES
  • Benign adnexal disease
  • Laparoscopy
03

In context

Lead sponsor

Imelda Hospital, Bonheiden is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All women aged 18 to 70 years regardless of parity with a symptomatic adnexal mass presumed to be benign based on ultrasound examination by applying the IOTA simple rules
  • All women aged 18 to 70 years regardless of parity with an asymptomatic persistent adnexal mass presumed to be benign based on ultrasound examination by applying the IOTA simple rules
  • Written obtained prior to surgery

Exclusion criteria

Exclusion Criteria:

  • History of hysterectomy by any technique
  • History of rectal surgery
  • Suspected rectovaginal endometriosis
  • Suspected endometriotic cyst
  • Solid adnexal mass
  • High suspicion of adnexal based on clinical, ultrasound or biochemical findings
  • History of pelvic inflammatory disease, especially prior tubo-ovarian or pouch of Douglas abscess
  • Active lower genital tract infection e.g. Chlamydia, N. gonorrhoeae
  • Virgo
  • Pregnancy
  • Need for other uterine surgical intervention (i.e. endometrial ablation, resection, myomectomy or hysterectomy)
  • Additional pathology necessitating hysterectomy
  • Failure to provide written prior to surgery
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    vNOTES adnexectomy

    Vaginal Natural Orifice Transluminal Endoscopic Surgery

    Procedure: vNOTES adnexectomy

  • Active comparator
    LSC adnexectomy

    Laparoscopic adnexectomy

    Procedure: Laparoscopic adnexectomy

Interventions

  • ProcedurevNOTES adnexectomy

    Surgical removal of one or both adnexa by a natural orifice transluminal endoscopic surgical technique using a colpotomy (transvaginal incision)

  • ProcedureLaparoscopic adnexectomy

    Surgical removal of one or both adnexa by transabdominal laparoscopy

06

What researchers measure

Primary outcomes

  1. Successful removal of adnexal mass without spill

    The proportion of women successfully treated by removing the adnexal mass without spill, using a dichotomous outcome measure, will be used as a measure of efficacy.

    Time frame: Intraoperative

Secondary outcomes

  1. Discharge from the hospital the day of the surgical intervention

    The proportion of women discharged the same day based on their own preference, as a dichotomous outcome. The decision to discharge or to admit to hospital for the night will be based solely on the choice of the woman to return home the same day or stay overnight.

    Time frame: Dichotomous outcome measured on the day of the surgical intervention

  2. Postoperative pain scores

    Postoperative pain scores, as an ordinal outcome, measured using a VAS scale twice daily from day 1 till 7 self-reported by the participating women

    Time frame: The first week after the surgical intervention

  3. The use of analgesics for postoperative pain

    Postoperative pain defined by the total amount of analgesics used as described in the standardized pain treatment protocol, as a continuous outcome.

    Time frame: The first week after the surgical intervention

  4. Postoperative infection

    Postoperative infection defined by lower abdominal pain with fever \> 38°C and positive clinical signs or laboratory findings, detected during the first six weeks of surgery, as a dichotomous outcome.

    Time frame: The first six weeks after the surgical intervention

  5. Complications

    Per- or postoperative complications according to the Clavien- Dindo classification detected during the first six weeks of surgery, as a dichotomous outcome

    Time frame: The first six weeks after the surgical intervention

  6. Hospital readmission

    The proportion of women readmitted to hospital within six weeks of surgery, as a dichotomous outcome

    Time frame: The first six weeks after the surgical intervention

  7. Pain during sexual intercourse

    Incidence and intensity of dyspareunia recorded by the participants at 3 and 6 months by self-reporting using a simple questionnaire and VAS scale, as a dichotomous and ordinal outcome

    Time frame: At baseline, 3 months and 6 months after the surgical intervention

  8. Sexual well being

    Sexual wellbeing at baseline, at 3 and 6 months by self-reporting using the SSFS (Short Sexual Function Scale).

    Time frame: At baseline, 3 months and 6 months after the surgical intervention

  9. Duration of the surgical intervention

    Duration of surgery measured as the time in minutes from the insertion of the bladder catheter to the end of vaginal/abdominal wound closure, as a continuous outcome

    Time frame: Intraoperative

  10. Direct and indirect costs

    Calculating the comparative direct costs of both techniques up to 6 weeks after the surgical intervention

    Time frame: Up to 6 weeks postoperative

  11. Health-related quality of life

    Health-related quality of life, at baseline, at 3 and 6 months by self-reporting the EQ-5D-3L questionnaire

    Time frame: At baseline, at 3 months and 6 months after the surgical intervention

07

Study locations

1 site
  • Imelda Hospital
    Bonheiden, Antwerp 2820, Belgium
08

References and documents

Publications

  • Wang PH, Lee WL, Juang CM, Tsai WY, Chao HT, Yuan CC. Excision of mature teratoma using culdotomy, with and without laparoscopy: a prospective randomised trial. BJOG. 2001 Jan;108(1):91-4. doi: 10.1111/j.1471-0528.2001.00003.x. PubMed 11213011 ↗
  • Baekelandt J. Poor man's NOTES: can it be a good approach for adhesiolysis? A first case report with video demonstration. J Minim Invasive Gynecol. 2015 Mar-Apr;22(3):319. doi: 10.1016/j.jmig.2014.11.001. Epub 2014 Nov 10. PubMed 25460516 ↗
  • Yang YS, Hur MH, Oh KY, Kim SY. Transvaginal natural orifice transluminal endoscopic surgery for adnexal masses. J Obstet Gynaecol Res. 2013 Dec;39(12):1604-9. doi: 10.1111/jog.12108. Epub 2013 Jul 22. PubMed 23875997 ↗
  • Ghezzi F, Cromi A, Uccella S, Bogani G, Serati M, Bolis P. Transumbilical versus transvaginal retrieval of surgical specimens at laparoscopy: a randomized trial. Am J Obstet Gynecol. 2012 Aug;207(2):112.e1-6. doi: 10.1016/j.ajog.2012.05.016. Epub 2012 May 23. PubMed 22704765 ↗
  • Medeiros LR, Rosa DD, Bozzetti MC, Fachel JM, Furness S, Garry R, Rosa MI, Stein AT. Laparoscopy versus laparotomy for benign ovarian tumour. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD004751. doi: 10.1002/14651858.CD004751.pub3. PubMed 19370607 ↗
  • Baekelandt JF, De Mulder PA, Le Roy I, Mathieu C, Laenen A, Enzlin P, Weyers S, Mol BWJ, Bosteels JJA. Transvaginal natural orifice transluminal endoscopic surgery (vNOTES) adnexectomy for benign pathology compared with laparoscopic excision (NOTABLE): a protocol for a randomised controlled trial. BMJ Open. 2018 Jan 10;8(1):e018059. doi: 10.1136/bmjopen-2017-018059. PubMed 29326183 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Interim analyses of major endpoints will be supplied, in strict confidence, to an independent Data Monitoring and Ethics Committee (DMEC) along with updates on results of other related studies, and any other analyses that the DMEC may request.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2016 to primary completion in Apr 2020, 50 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2015
First posted
Dec 15, 2015
StartActual
Feb 3, 2016
Primary completionActual
Apr 16, 2020
CompletionActual
Apr 16, 2020
Last update
Jun 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02630329
Lead sponsor
Imelda Hospital, Bonheiden
Responsible party
Dr Jan Baekelandt, MD (Dr, Imelda Hospital, Bonheiden) — Principal investigator
First posted
Dec 15, 2015
Start date
Feb 3, 2016
Primary completion
Apr 16, 2020
Completion
Apr 16, 2020
Last update
Jun 11, 2020

Study contacts

Jan Baekelandt, MD
principal investigator · Imelda Hospital, Bonheiden

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion